Business
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
BASKING RIDGE, N.J., May 22, 2025--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25).
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/15c642a36d9a31837c18b004eb2f9e82"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AzQ44up2pZ7n_0cvizcxRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/15c642a36d9a31837c18b004eb2f9e82","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Late-breaking data from DESTINY-Breast09 and DESTINY-Gastric04 phase 3 trials showcase how ENHERTU will potentially redefine standard of care for first-line HER2 positive metastatic breast cancer and second-line HER2 positive metastatic gastric cancer","length":251,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Investor meeting to discuss ASCO presentations and oncology development updates","length":79,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":330,"olType":false},{"type":"text","content":"BASKING RIDGE, N.J., May 22, 2025--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25).","length":271,"tagName":"p"},{"type":"text","content":"Data at ASCO showcasing the company’s progress towards creating new standards of care for patients with cancer will include two late-breaking oral presentations. The first will feature results of the DESTINY-Breast09 phase 3 trial (LBA #1008) where ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab demonstrated superior progression-free survival compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer. The second will highlight results of the DESTINY-Gastric04 phase 3 trial (LBA #4002) where ENHERTU demonstrated superior overall survival compared to ramucirumab and paclitaxel as a second-line treatment in patients with HER2 positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Data from DESTINY-Breast09 and DESTINY-Gastric04 will be featured in ASCO press briefings.","length":893,"tagName":"p"},{"type":"text","content":""This y...